Published • loading... • Updated
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer said the drug produced up to 15.9% weight loss in a 32-week extension and showed low gastrointestinal side effects.
- On Saturday, Pfizer presented detailed results from multiple Phase 2b studies of berobenatide at the 86th Scientific Sessions of the American Diabetes Association in New Orleans.
- The experimental drug sits at the center of Pfizer's obesity strategy following its $10 billion acquisition of Metsera last year, as the company seeks to differentiate berobenatide from weekly injections through monthly dosing.
- Data from the VESPER-3 study showed a mean nausea rate around 38% and vomiting rate of about 23.3%, comparable to Novo Nordisk's Wegovy, which reported around 44% nausea and around 25% vomiting.
- Study lead author John Buse, MD, PhD, noted that "for patients, this less frequent dosing may help ease the burden of ongoing treatment and support better long-term adherence" in chronic weight management.
- Pfizer plans to advance 20+ trials for obesity and related comorbidities in 2026, including 10 ongoing and planned Phase 3 studies for berobenatide targeting conditions like knee osteoarthritis and obstructive sleep apnea.
Insights by Ground AI
14 Articles
14 Articles
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy
Pfizer executives said most patients experienced few or mild side effects, with gastrointestinal events largely limited to early doses and clustered close to when patients received the shot.
·Chicago, United States
Read Full Article
Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough
TLDR Pfizer presented Phase 2b results for berobenatide, a monthly GLP-1 injection demonstrating approximately 15% weight reduction in clinical studies The therapy may become the first-ever monthly obesity treatment in its category, rivaling weekly alternatives such as Wegovy and Zepbound Over 20 clinical trials in obesity and metabolic diseases are scheduled for 2026, including 10 Phase 3 berobenatide studies The pharmaceutical giant struck a …
Coverage Details
Total News Sources14
Leaning Left0Leaning Right1Center8Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
C 89%
11%
Factuality
To view factuality data please Upgrade to Premium
